RTW Investments LP boosted its holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 11.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,621,996 shares of the company's stock after acquiring an additional 363,636 shares during the quarter. Spyre Therapeutics accounts for approximately 1.3% of RTW Investments LP's investment portfolio, making the stock its 26th biggest holding. RTW Investments LP owned 7.04% of Spyre Therapeutics worth $84,320,000 as of its most recent SEC filing.
Several other large investors have also added to or reduced their stakes in the business. Huntington National Bank bought a new position in shares of Spyre Therapeutics during the 4th quarter worth approximately $34,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in Spyre Therapeutics in the fourth quarter worth $46,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Spyre Therapeutics during the 4th quarter valued at $182,000. Tower Research Capital LLC TRC increased its position in shares of Spyre Therapeutics by 1,548.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,574 shares of the company's stock valued at $200,000 after purchasing an additional 8,054 shares during the last quarter. Finally, Arizona State Retirement System raised its stake in shares of Spyre Therapeutics by 38.4% during the 4th quarter. Arizona State Retirement System now owns 10,115 shares of the company's stock worth $235,000 after purchasing an additional 2,805 shares during the period. Institutional investors own 80.39% of the company's stock.
Wall Street Analyst Weigh In
SYRE has been the subject of several research reports. Leerink Partnrs upgraded shares of Spyre Therapeutics to a "strong-buy" rating in a research report on Tuesday, April 8th. Wedbush restated an "outperform" rating and set a $65.00 price target on shares of Spyre Therapeutics in a research note on Monday, May 5th. Leerink Partners assumed coverage on shares of Spyre Therapeutics in a report on Tuesday, April 8th. They issued an "outperform" rating and a $45.00 price target on the stock. Wolfe Research initiated coverage on Spyre Therapeutics in a report on Tuesday, March 18th. They set an "outperform" rating and a $27.00 price objective for the company. Finally, The Goldman Sachs Group raised Spyre Therapeutics to a "strong-buy" rating in a research report on Tuesday, February 18th. Six equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $53.40.
Read Our Latest Analysis on Spyre Therapeutics
Spyre Therapeutics Stock Performance
Spyre Therapeutics stock traded down $0.30 during mid-day trading on Monday, reaching $14.88. The company's stock had a trading volume of 338,924 shares, compared to its average volume of 612,733. Spyre Therapeutics, Inc. has a 12-month low of $10.91 and a 12-month high of $40.26. The company has a market capitalization of $896.91 million, a P/E ratio of -1.99 and a beta of 2.78. The firm's fifty day moving average price is $14.84 and its two-hundred day moving average price is $21.17.
Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.74) earnings per share for the quarter, beating analysts' consensus estimates of ($0.76) by $0.02. On average, research analysts predict that Spyre Therapeutics, Inc. will post -4.46 EPS for the current fiscal year.
Spyre Therapeutics Company Profile
(
Free Report)
Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).
Featured Stories
Before you consider Spyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spyre Therapeutics wasn't on the list.
While Spyre Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
